Novo Nordisk A/S (NVO)
112.12
+3.69 (+3.40%)
USD |
NYSE |
Jun 24, 16:00
112.10
-0.02 (-0.02%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 253.98B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 38.44% |
Valuation | |
PE Ratio | 33.38 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 11.07 |
Price to Book Value | 25.43 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 1.022 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.3829 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 28.40% |
News
Headline
Wire
Time (ET)
Yahoo
06/23 08:00
SA Breaking News
06/23 06:03
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
08/04/2022 | -- | Results | Q2 2022 | -- | 0.83 | -- | |
08/04/2022 | -- | Earnings Call | Q2 2022 | -- | -- | -- | |
02/02/2022 | -- | Results | Q4 2021 | 0.72 | 0.72 | 0.74% | |
02/02/2022 | 07:00 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
11/03/2021 | -- | Results | Q3 2021 | -- | 0.80 | -- | |
11/03/2021 | 08:00 EST | Earnings Call | Q3 2021 | -- | -- | -- | |
08/06/2021 | 07:00 EST | Earnings Call | Q2 2021 | -- | -- | -- | |
08/04/2021 | -- | Results | Q2 2021 | 0.84 | 0.76 | 10.47% |
*Estimated Date/Time
Earnings
Profile
Edit
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
URL | https://www.novonordisk.com |
Investor Relations URL | https://www.novonordisk.com/investors.html |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Large Cap/Growth |
Next Earnings Release | Aug. 04, 2022 |
Last Earnings Release | Feb. 02, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 25, 2022 |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | 1.578 |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.99 |
Yield to Sector | 0.661 |
Yield to Industry | 2.022 |
Last Dividend Amt. | 1.022 |
Dividend Frequency | Semi-Annually |
Last Ex-Dividend Date | Mar. 25, 2022 |
Yield (TTM) | 1.40% |
Forward Yield | 1.40% |
Payout Ratio | 46.76% |
Cash Payout Ratio | 38.81% |
Consistent Payer (5Y) |
|
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 24, 2022.
Fundamentals
Revenue (TTM) | 23.24B |
Total Expenses (TTM) | 13.44B |
Net Income (TTM) | 7.705B |
Total Assets (Quarterly) | 29.58B |
Total Liabilities (Quarterly) | 19.60B |
Shareholders Equity (Quarterly) | 9.987B |
Cash from Operations (TTM) | 10.49B |
Cash from Investing (TTM) | -4.752B |
Cash from Financing (TTM) | -4.597B |
Ratings
Profile
Edit
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
URL | https://www.novonordisk.com |
Investor Relations URL | https://www.novonordisk.com/investors.html |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Large Cap/Growth |
Next Earnings Release | Aug. 04, 2022 |
Last Earnings Release | Feb. 02, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 25, 2022 |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Top Fund Holders
Symbol | Dollars Invested | % Weight |
---|---|---|
LIFE.TO | 11.38M USD | 4.89% |
PPH | 24.72M USD | 4.83% |
PJHRX | 75.86M USD | 4.46% |
AMIGX | 110.64M USD | 3.49% |
THW | 17.05M USD | 3.09% |
HRINX | 77.40M USD | 1.88% |
CHW | 11.83M USD | 1.59% |
LGLQX | 98.52M USD | 1.48% |
ETG | 22.54M USD | 1.27% |
DFALX | 57.91M USD | 1.06% |
AVDE | 11.04M USD | 0.80% |
DFIEX | 169.69M USD | 0.54% |
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Morningstar | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
NVO Tweets |